The COVID-19 pandemic has significantly increased mortality in many countries, with the number of infected cases increasing exponentially worldwide. One of the main determining factors of the poor prognosis in these patients is the development of coagulopathy. Moreover, it is well known that assisted reproductive technology procedures confer a risk of thromboembolic complications. This commentary analyses specific aspects coexisting between the thrombotic risk described during virus infection and that reported in the context of assisted reproduction treatments. Based on known pathophysiological aspects of virus infection and of ovarian stimulation, there are common elements that deserve to be taken into account. In the present context, any risk of hyperstimulation should be avoided. Gonadotrophin-releasing hormone agonist triggering should be mandatory in high-responder patients and/or those with COVID-19 infection. In both cases, the cycle should be segmented. A proposal is made for the use of prophylactic low molecular weight heparin not only in those cases in which oocyte retrieval has been performed, but also in those in which cancellation has been decided. In addition, endometrial preparation for frozen-thawed embryo transfers should use the transdermal route in order to minimize the higher thrombotic risk associated with the oral route.

在许多国家，COVID-19大流行大大增加了死亡率，全世界感染病例的数量呈指数增长。这些患者预后不良的主要决定因素之一是凝血病的发展。此外，众所周知，辅助生殖技术程序具有血栓栓塞并发症的风险。该评论分析了病毒感染期间描述的血栓形成风险与辅助生殖治疗中报道的血栓形成风险之间共存的具体方面。基于病毒感染和卵巢刺激的已知病理生理学方面，有一些共同的因素值得考虑。在当前情况下，应避免任何过度刺激的风险。促性腺激素释放激素激动剂触发应在高应答患者和/或COVID-19感染患者中强制执行。在这两种情况下，都应将循环分段。提出了不仅在已经进行卵母细胞取回的情况下，而且在已经决定取消卵母细胞的情况下，预防性使用低分子量肝素的提议。此外，用于冷冻解冻胚胎移植的子宫内膜制剂应使用经皮途径，以最大程度地降低与口服途径相关的血栓形成风险。但也可以决定取消。此外，用于冷冻解冻胚胎移植的子宫内膜制剂应使用经皮途径，以最大程度地降低与口服途径相关的血栓形成风险。但也可以决定取消。此外，用于冷冻解冻胚胎移植的子宫内膜制剂应使用经皮途径，以最大程度地降低与口服途径相关的血栓形成风险。